Volume | 13,787 |
|
|||||
News | - | ||||||
Day High | 11.75 | Low High |
|||||
Day Low | 11.14 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Oculis Holding AG | OCS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
11.72 | 11.14 | 11.75 | 11.75 | 11.75 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
123 | 13,787 | US$ 11.51 | US$ 158,671 | - | 9.05 - 14.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 213 | US$ 11.75 | USD |
Oculis Holding AG Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 430.63M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Oculis News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.95 | 12.00 | 11.14 | 11.89 | 7,792 | -0.20 | -1.67% |
1 Month | 11.86 | 12.0796 | 11.14 | 11.88 | 8,933 | -0.11 | -0.93% |
3 Months | 11.69 | 13.30 | 10.55 | 11.97 | 38,834 | 0.06 | 0.51% |
6 Months | 10.15 | 14.465 | 9.60 | 12.09 | 36,556 | 1.60 | 15.76% |
1 Year | 12.75 | 14.50 | 9.05 | 11.92 | 27,750 | -1.00 | -7.84% |
3 Years | 10.95 | 14.50 | 6.26 | 11.50 | 27,604 | 0.80 | 7.31% |
5 Years | 10.95 | 14.50 | 6.26 | 11.50 | 27,604 | 0.80 | 7.31% |
Oculis Description
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. |